Search

Background Some pregnant smokers try e-cigarettes, but effectiveness and safety of such use are unknown. Objectives To compare effectiveness and safety of nicotine patches and e-cigarettes in pregnancy. Design A pragmatic multi-centre randomised controlled trial. Setting Twenty-three hospitals across England, and a Stop Smoking Service in Scotland. Participants One thousand one hundred and forty pregnant daily smokers (12–24 weeks’ gestation) motivated to stop smoking, with no strong preference for using nicotine patches or e-cigarettes. Interventions Participants in the e-cigarette arm were posted a refillable e-cigarette device with two 10 ml bottles of tobacco-flavoured e-liquid (18 mg nicotine). Participants in the nicotine patches arm were posted a 2-week supply of 15 mg/16-hour nicotine patches. Supplies were provided for up to 8 weeks. Participants sourced further supplies themselves as needed. Participants in both arms received support calls prior to their target quit date, on the quit date, and weekly for the next 4 weeks. Outcome measures The primary outcome was validated prolonged abstinence at the end of pregnancy. Participants lost to follow-up or not providing biochemical validation were included as non-abstainers. Secondary outcomes included self-reported abstinence at different time points, treatment adherence and safety outcomes. Results Only 55% of self-reported abstainers mailed back useable saliva samples. Due to this, validated sustained abstinence rates were low (6.8% vs. 4.4% in the e-cigarettes and nicotine patches arms, respectively, risk ratio = 1.55, 95% confidence interval 0.95 to 2.53; Bayes factor = 2.7). In a pre-specified sensitivity analysis that excluded abstainers using non-allocated products, the difference became significant (6.8% vs. 3.6%, risk ratio = 1.93, 95% confidence interval 1.14 to 3.26; Bayes factor = 10). Almost a third of the sample did not set a target quit date and the uptake of support calls was low, as was the initial product use. At end of pregnancy, 33.8% versus 5.6% of participants were using their allocated product in the e-cigarettes versus nicotine patches arm (risk ratio = 6.01, 95% confidence interval 4.21 to 8.58). Regular use of e-cigarettes in the nicotine patches arm was more common than use of nicotine replacement products in the e-cigarette arm (17.8% vs. 2.8%). Rates of adverse events and adverse birth outcomes were similar in the two study arms, apart from participants in the e-cigarette arm having fewer infants with low birthweight (

Background: Physical activity can support smoking cessation for smokers wanting to quit, but there have been no studies on supporting smokers wanting only to reduce. More broadly, the effect of motivational support for such smokers is unclear. Objectives The objectives were to determine if motivational support to increase physical activity and reduce smoking for smokers not wanting to immediately quit helps reduce smoking and increase abstinence and physical activity, and to determine if this intervention is cost-effective. Design This was a multicentred, two-arm, parallel-group, randomised (1 : 1) controlled superiority trial with accompanying trial-based and model-based economic evaluations, and a process evaluation. Setting and participants Participants from health and other community settings in four English cities received either the intervention (n = 457) or usual support (n = 458). Intervention The intervention consisted of up to eight face-to-face or telephone behavioural support sessions to reduce smoking and increase physical activity. Main outcome measures The main outcome measures were carbon monoxide-verified 6- and 12-month floating prolonged abstinence (primary outcome), self-reported number of cigarettes smoked per day, number of quit attempts and carbon monoxide-verified abstinence at 3 and 9 months. Furthermore, self-reported (3 and 9 months) and accelerometer-recorded (3 months) physical activity data were gathered. Process items, intervention costs and cost-effectiveness were also assessed. Results The average age of the sample was 49.8 years, and participants were predominantly from areas with socioeconomic deprivation and were moderately heavy smokers. The intervention was delivered with good fidelity. Few participants achieved carbon monoxide-verified 6-month prolonged abstinence [nine (2.0%) in the intervention group and four (0.9%) in the control group; adjusted odds ratio 2.30 (95% confidence interval 0.70 to 7.56)] or 12-month prolonged abstinence [six (1.3%) in the intervention group and one (0.2%) in the control group; adjusted odds ratio 6.33 (95% confidence interval 0.76 to 53.10)]. At 3 months, the intervention participants smoked fewer cigarettes than the control participants (21.1 vs. 26.8 per day). Intervention participants were more likely to reduce cigarettes by ≥ 50% by 3 months [18.9% vs. 10.5%; adjusted odds ratio 1.98 (95% confidence interval 1.35 to 2.90] and 9 months [14.4% vs. 10.0%; adjusted odds ratio 1.52 (95% confidence interval 1.01 to 2.29)], and reported more moderate-to-vigorous physical activity at 3 months [adjusted weekly mean difference of 81.61 minutes (95% confidence interval 28.75 to 134.47 minutes)], but not at 9 months. Increased physical activity did not mediate intervention effects on smoking. The intervention positively influenced most smoking and physical activity beliefs, with some intervention effects mediating changes in smoking and physical activity outcomes. The average intervention cost was estimated to be £239.18 per person, with an overall additional cost of £173.50 (95% confidence interval −£353.82 to £513.77) when considering intervention and health-care costs. The 1.1% absolute between-group difference in carbon monoxide-verified 6-month prolonged abstinence provided a small gain in lifetime quality-adjusted life-years (0.006), and a minimal saving in lifetime health-care costs (net saving £236). Conclusions There was no evidence that behavioural support for smoking reduction and increased physical activity led to meaningful increases in prolonged abstinence among smokers with no immediate plans to quit smoking. The intervention is not cost-effective. Limitations Prolonged abstinence rates were much lower than expected, meaning that the trial was underpowered to provide confidence that the intervention doubled prolonged abstinence. Future work Further research should explore the effects of the present intervention to support smokers who want to reduce prior to quitting, and/or extend the support available for prolonged reduction and abstinence. Trial registration This trial is registered as ISRCTN47776579. Funding This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in Health Technology Assessment; Vol. 27, No. 4. See the NIHR Journals Library website for further project information. Plain language summary: NHS pharmacological and behavioural support helps smokers wanting to quit, and physical activity may also help. It is unclear if behavioural support for those not ready to quit may lead to more quit attempts and abstinence from smoking. A total of 915 smokers who wanted to reduce their smoking, but who had not yet quit, were recruited and randomised to receive an intervention or brief support as usual (brief advice to quit), in Plymouth, London, Oxford and Nottingham. The intervention involved up to eight sessions (by telephone or in person) of motivational support to reduce smoking and increase physical activity (and more sessions to support a quit attempt). Participants self-reported smoking and physical activity information at the start of the trial and after 3 and 9 months. Self-reported quitters confirmed their abstinence with a biochemical test of expired air or saliva. Our main interest was in whether or not the groups differed in the proportion who remained abstinent for at least 6 months. Overall, only 1–2% remained abstinent for 6 months. Although it appeared that a greater proportion did so after receiving the intervention, because few participants were abstinent, the results are not conclusive. However, the intervention had beneficial effects on less rigorous outcomes, including a reduction in the self-reported number of cigarettes smoked, and a greater proportion of intervention than control participants with self-reported and biochemically verified abstinence at 3 months. The intervention also helped participants to reduce, by at least half, the number of cigarettes they smoked at 3 and 9 months, and to report more physical activity, but only at 3 months. Despite reasonable intervention engagement and some short-term changes in smoking and physical activity, the trial does not provide evidence that this intervention would help smokers to quit for at least 6 months nor would it be cost-effective, with an average cost of £239 per smoker. Scientific summary: Background Behavioural support to aid smoking cessation is an effective and cost-effective intervention for smokers wanting to quit. Motivational support can reduce smoking, with greater reductions leading to successful quitting, but the evidence is fairly weak for those not wanting to immediately quit. Smoking reduction studies may involve two types of smokers: (1) those who want to quit and are willing to reduce first rather than quit abruptly and (2) those who do not want to quit (immediately) but are interested in smoking reduction or harm reduction. At least four studies have investigated the effects of behavioural support for smokers wanting to reduce but not quit, and provide imprecise or no evidence of effects on smoking reduction, quitting and sustained abstinence. Exercise has been shown to aid smoking cessation for those wanting to quit, but there is only exploratory evidence that promoting physical activity (PA) and supporting smoking reduction can facilitate smoking reduction and quitting. A definitive study is needed to determine the effectiveness and cost-effectiveness of behavioural support for smoking reduction and increasing PA, on smoking outcomes, especially prolonged, carbon monoxide-verified smoking abstinence. Objectives The overall aim of the Trial of physical Activity-assisted Reduction of Smoking (TARS) was to determine if adding a motivational intervention to reduce smoking and increase PA to usual support was more effective and cost-effective in facilitating carbon monoxide-verified 6-month floating prolonged abstinence. The specific research questions were as follows. Compared with usual support, did the TARS intervention: increase the proportion of participants achieving carbon monoxide-verified 6-month floating prolonged abstinence at 9 months post baseline? increase the proportion of participants reporting a ≥ 50% reduction in the number of cigarettes smoked (between baseline and 3 months, and baseline and 9 months)? increase the proportion of participants achieving carbon monoxide-verified 12-month floating prolonged abstinence at 15 months post baseline? increase the proportion of participants achieving self-reported and carbon monoxide-verified point prevalence abstinence at 3 and 9 months post baseline? increase self-reported PA at 3 and 9 months post baseline, and accelerometer-assessed PA at 3 months post baseline? improve body mass index, quality of life, sleep, cigarette cravings and other beliefs about smoking and PA at 3 and 9 months post baseline? What were the intervention, health-care and social care costs, compared with support as usual, at 9 months post baseline? Was the intervention cost-effective, compared with usual support, (1) at 9 months, and (2) over a longer-term/lifetime horizon? Were the trial methods and intervention acceptable and feasible, based on an embedded internal pilot phase? Did the intervention demonstrate good fidelity (design, training, delivery, receipt and enactment) and acceptability and what were the mechanisms of action of the intervention? Methods The study involved a multicentred, parallel, two-group, individually randomised controlled, superiority trial with a mixed-methods embedded process evaluation and economic evaluations. Recruitment took place over 16 months from January 2018, with follow-up assessments ending in October 2020 (with only minimal overlap with COVID-19 restrictions) around four English cities: Plymouth, Nottingham, London and Oxford. Intervention participants were offered up to eight face-to-face or telephone behavioural support sessions to reduce smoking and increase PA, with up to six additional sessions if a participant wanted support with cessation. Substantial patient and public involvement supported both the development and evaluation of a pilot trial of the intervention, and adaptations for the present intervention. An intervention manual underpinned the training and remote supervision of eight health trainers (HTs) across four sites, and all aspects of intervention fidelity (design, training, receipt, delivery and enactment) were assessed. The client-centred intervention was informed by motivational interviewing and linked to self-determination theory. It aimed to empower participants to decide what support they required, and where, when and for how long, and, if the participant became ready to quit, to provide appropriate support. Control participants received brief advice on smoking cessation. Participants were recruited from primary and secondary care and community settings. Participants were adult smokers (≥ 18 years) who smoked ≥ 10 cigarettes per day (for at least 1 year), who wanted to reduce smoking but not quit immediately. Smokers were ineligible if they were unable to engage in at least 15 minutes of moderate-intensity PA, had any illness or injury that might be exacerbated by exercise, or were unable to engage in the trial and/or the intervention because of a language barrier or for other reasons. Following screening and consent, participants completed baseline assessments face to face or via telephone. At 3 and 9 months post baseline, participants were posted a questionnaire (and an accelerometer at 3 months for a random sample). Participants reporting having made a quit attempt and not having smoked at follow-up were invited to complete a biochemical verification of abstinence. Most did this with a carbon monoxide expired air test, but a few were posted a saliva cotinine test kit late in the trial as a result of COVID-19 restrictions. Those with carbon monoxide-verified abstinence at 9 months were also followed up at 15 months. The primary outcome was carbon monoxide-verified 6-month floating prolonged (i.e. with no fixed quit date) abstinence between 3 and 9 months. Other smoking measures were carbon monoxide-verified 12-month floating prolonged abstinence, point prevalence self-reported abstinence and number of cigarettes smoked per day, and carbon monoxide-verified abstinence and number of quit attempts at both 3 and 9 months. Analyses of smoking abstinence outcomes were in line with the Russell Standard, with non-responders assumed to be still smoking. Self-reported (3 and 9 months) and accelerometer-recorded (3 months) PA, body mass index, sleep and quality of life were also assessed at 3 and 9 months. The embedded mixed-methods process evaluation was split into two phases: (1) an initial evaluation linked to the internal pilot phase and (2) the subsequent main trial phase, with four workstreams as follows – (1) data related to levels of intervention engagement; (2) assessment of intervention delivery, receipt and enactment fidelity, using survey items related to the intervention logic model and recorded intervention sessions; (3) mediation analyses of changes in PA and process measures on outcomes; and (4) an embedded qualitative study with HT and intervention participant interviews. The health economic evaluation included an estimation of the cost of delivering the intervention from data collected during the trial, supplemented by investigator estimates. A trial-based economic evaluation was conducted using patient-reported resource use and health-related quality of life (EuroQol-5 Dimensions, five-level version), collected in questionnaire booklets at baseline and at 3 and 9 months post randomisation. Aggregate costs and quality-adjusted life-years (QALYs) over a 9-month time horizon were estimated and regression methods were used to adjust for potential confounders. A decision-analytic model was developed following a review of the existing literature. Smoking cessation rates were assumed to affect rates of coronary obstructive pulmonary disease, coronary heart disease, stroke and lung cancer, as well as quality of life and other smoking-related causes of mortality. Lifetime costs and QALYs were estimated. Results The sample (n = 915) had a mean age of 49.8 [standard deviation (SD) 13.9] years; 55% were female and 85% identified as white. Sixty per cent lived within one of the four highest-ranked deciles for social deprivation. They initially smoked an average of 18.0 cigarettes daily, with 77.68% smoking within 30 minutes of waking, and reported doing a median of 337 minutes of moderate to vigorous physical activity (MVPA) weekly. Primary analysis Using the Russell Standard, assuming missing participant data at follow-up implied continued smoking, 0.9% (n = 4) of control and 2.0% (n = 9) of intervention participants achieved carbon monoxide-verified 6-month floating prolonged abstinence between 3 and 9 months. This difference was not statistically significant [fully adjusted estimated odds ratio 2.30, 95% confidence interval (CI) 0.70 to 7.56; p = 0.169]. Including participants who achieved the outcome between 9 and 15 months increased this to 2.2% (n = 10) and 3.1% (n = 14) in the control and intervention groups, respectively, which was also not statistically significantly different (fully adjusted estimated odds ratio 1.43, 95% CI 0.62 to 3.26; p = 0.398). For the 19 and 20 participants followed up at 15 months, 0.2% (n = 1) and 1.3% (n = 6) of the overall control and intervention groups, respectively, achieved carbon monoxide-verified 12-month floating prolonged abstinence, which was also not statistically significantly different (fully adjusted estimated odds ratio 6.3, 95% CI 0.8 to 53.1; p = 0.089). Secondary outcomes The intervention had weak effects on self-reported 7-day point prevalence abstinence at 3 months (5.5% vs. 2.9%, adjusted odds ratio 1.99, 95% CI 1.00 to 3.94; p = 0.049), but there was no evidence of a statistically significant effect on carbon monoxide-verified point prevalence abstinence at 3 months (3.7% vs. 1.8%, adjusted odds ratio 2.19, 95% CI 0.93 to 5.14; p = 0.071). Nor was there an intervention effect at 9 or 15 months, compared with control, for either of these outcomes. The intervention group reported smoking fewer cigarettes daily than the control group at 3 months (adjusted mean difference –5.62, 95% CI –9.80 to –1.44; p = 0.009), but not at 9 months (adjusted mean difference 0.95, 95% CI –5.37 to 3.46; p = 0.671). A greater proportion of intervention participants reported having reduced their daily number of cigarettes smoked by at least 50%, up to 3 months (18.9% vs. 10.5%, adjusted odds ratio 1.98, 95% CI 1.35 to 2.90; p

Cigarette smoking remains the leading behavioral risk factor for chronic disease and premature mortality. This RCT tested the efficacy of moderate intensity aerobic exercise as an adjunctive smoking cessation treatment among women. Participants (N = 105; age = 42.5, SD = 11.2) received brief smoking cessation counseling and 10 weeks of nicotine replacement therapy and were randomized to 12 weeks of moderate intensity exercise (Exercise; n = 53) or 12 weeks of health education (Control; n = 52). Longitudinal models, with Generalized Estimating Equations, showed no differences between Exercise and Control in cotinine-verified 7-day point prevalence abstinence (Wald = 1.96, p = 0.10) or continuous abstinence (Wald = 1.45, p = 0.23) at 12-weeks (post-treatment) or 6-, 9-, or 12-month follow-up, controlling for differences in baseline nicotine dependence. There was no effect of exercise on smoking cessation. The present study adds to the literature suggesting null effects of exercise as a smoking cessation adjunctive treatment despite promising findings in short-term laboratory based studies., Author(s): Shira Dunsiger [sup.1] , Jessica A. Emerson [sup.1] , Michael Ussher [sup.2] [sup.3] , Bess H. Marcus [sup.1] , Robert Jr Miranda [sup.4] , Peter M. Monti [sup.1] , [...]

Introduction: Vaccination during pregnancy protects both the mother and the foetus from vaccine-preventable diseases. However, uptake of the recommended vaccines (influenza, pertussis, COVID-19) by pregnant women remains low in Europe and the USA. Understanding the reasons for this is crucial to inform strategies to increase vaccination rates in pregnant women. This qualitative systematic review aimed to identify the barriers and facilitators to vaccination against influenza, pertussis/whooping cough and COVID-19 during pregnancy and identify possible strategies to increase vaccination rates. Methods: We conducted a comprehensive search of electronic databases, including Medline, PsycINFO, CINAHL, Web of Science, WHO database, Embase and grey literature to identify qualitative studies that explored barriers and facilitators to vaccine uptake among pregnant women (PROSPERO CRD42023399488). The search was limited to studies published between 2012 and 2022 conducted in high-income countries with established vaccination programmes during pregnancy. Studies were thematically analysed and underwent quality assessment using the Joanna Briggs Institute validated critical appraisal tool for qualitative research. Results: Out of 2681 articles screened, 28 studies (n = 1573 participants) were eligible for inclusion. Five overarching themes emerged relating to personal, provider and systemic factors. Barriers to vaccine uptake included concerns about vaccine safety and efficacy, lack of knowledge about vaccines' benefits and necessity, fear of adverse effects on the foetus or mother and low perception of disease severity. Facilitators included recommendations from trusted healthcare providers, easy access to vaccination, clear communication on the benefits and safety of vaccination, and positive social influences from family and friends. Strategies for increasing vaccination uptake included strong and proactive vaccine recommendations by trusted healthcare professionals, provision of vaccines during routine antenatal care, and clear and consistent communication about vaccines addressing pregnant women's concerns. Conclusion: This review highlights the need for interventions that address the identified barriers to vaccine uptake among pregnant women. Recommendation from a healthcare provider can play a significant role in promoting vaccine uptake, as can clear risk/benefit communication and convenient access to vaccination. Addressing concerns about vaccine safety and providing accurate information about vaccines is also important. [ABSTRACT FROM AUTHOR]

A survey of UK public health system maternity care providers has found that there is inconsistent and conflicting advice regarding infant skincare in the country. The survey revealed that there is no consensus on when to bathe newborns, with recommendations ranging from delaying the first bath for 24 hours to delaying it for up to 2 weeks. There is also variation in recommendations regarding the use of cleansing products and the removal of vernix. The study emphasizes the need for standardized and evidence-based guidelines for infant skincare in the UK. [Extracted from the article]

The article discusses the BabyBathe study, which aims to develop an intervention to reduce infant bathing frequency in order to prevent eczema. Eczema is a chronic skin condition that affects a significant number of infants and children worldwide. The study protocol involves working with pregnant women to develop an acceptable intervention and conducting a randomized controlled feasibility trial to assess the willingness, adherence, and acceptability of the intervention. The article highlights the negative effects of frequent bathing on skin physiology and the potential benefits of reducing bathing frequency and intensity. The results of the feasibility trial will inform the possibility of conducting a larger-scale trial. The study is funded by the NIHR Research for Patient Benefit program. [Extracted from the article]

Abstract Background Many women try to stop smoking in pregnancy but fail. One difficulty is that there is insufficient evidence that medications for smoking cessation are effective and safe in pregnancy and thus many women prefer to avoid these. Physical activity (PA) interventions may assist cessation; however, trials examining these interventions have been too small to detect or exclude plausible beneficial effects. The London Exercise And Pregnant smokers (LEAP) trial is investigating whether a PA intervention is effective and cost-effective when used for smoking cessation by pregnant women, and will be the largest study of its kind to date. Methods/design The LEAP study is a pragmatic, multi-center, two-arm, randomized, controlled trial that will target pregnant women who smoke at least one cigarette a day (and at least five cigarettes a day before pregnancy), and are between 10 and 24 weeks pregnant. Eligible patients are individually randomized to either usual care (that is, behavioral support for smoking cessation) or usual care plus a intervention (entailing supervised exercise on a treadmill plus PA consultations). The primary outcome of the trial is self-reported and biochemically validated continuous abstinence from smoking between a specified quit date and the end of pregnancy. The secondary outcomes, measured at 1 and 4 weeks after the quit date, and at the end of pregnancy and 6 months after childbirth, are PA levels, depression, self-confidence, and cigarette withdrawal symptoms. Smoking status will also be self-reported at 6 months after childbirth. In addition, perinatal measures will be collected, including antenatal complications, duration of labor, mode of delivery, and birth and placental weight. Outcomes will be analyzed on an intention-to-treat basis, and logistic regression models used to compare treatment effects on the primary outcome. Discussion This trial will assess whether a PA intervention is effective when used for smoking cessation during pregnancy. Trial registration ISRCTN48600346

Objectives Smoking during pregnancy is harmful for the woman and the unborn child, and the harms raise risks for the child going forward. Indigenous women often have higher rates of smoking prevalence than non-indigenous. Exercise has been proposed as a strategy to help pregnant smokers to quit. Maori (New Zealand Indigenous) women have high rates of physical activity suggesting that an exercise programme to aid quitting could be an attractive initiative. This study explored attitudes towards an exercise programme to aid smoking cessation for Maori pregnant women. Methods Focus groups with Maori pregnant women, and key stakeholder interviews were conducted. Results Overall, participants were supportive of the idea of a physical activity programme for pregnant Maori smokers to aid smoking cessation. The principal, over-arching finding, consistent across all participants, was the critical need for a Kaupapa Maori approach (designed and run by Maori, for Maori people) for successful programme delivery, whereby Maori cultural values are respected and infused throughout all aspects of the programme. A number of practical and environmental barriers to attendance were raised including: cost, the timing of the programme, accessibility, transport, and childcare considerations. Conclusions A feasibility study is needed to design an intervention following the suggestions presented in this paper with effort given to minimising the negative impact of barriers to attendance., Author(s): Vaughan Roberts [sup.1] , Marewa Glover [sup.2] , Lesley McCowan [sup.3] , Natalie Walker [sup.1] , Michael Ussher [sup.4] , Ihirangi Heke [sup.5] , Ralph Maddison [sup.1] [sup.6] Author [...]